Prescription drug Trasylol was manufactured by Bayer Pharmaceuticals and is used to reduce bleeding and blood clotting in patients during heart surgery. In the May 29, 2008 issue of the New England Journal of Medicine, a study noted a significant increase in the risk of death from kidney failure, heart attack and stroke.
The study was terminated early because of ethical concerns raised after the research showed that prescrption drug Trasylol doubled the risk of death versus the alternatives. The lead researcher Dsaid, "There was no way we could ethically enroll more patients in the trial because we had our answer."
After the initial reports were given to the FDA in November 2007, Bayer agreed to temporarily suspend sales and marketing of the prescription drug Trasylol. Bayer has now notified the FDA that it will begin removing the remaining presciption drug Trasylol stock in the U.S. Market from hospitals, warehouses and physicians' supplies.
Posted by Louisville, Kentucky lawyer: Larry Jones 1-888-KYLAW22
